Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.35 |
| ▸ | TUBB | P07437 | 4/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750019 | 1.00 | NFE2L2 (0.38) | NFE2L2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29861038 | 0.79 | LMNA (0.45) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL21750003 | 0.79 | LMNA (0.45) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL17299112 | 0.75 | TUBB1 (0.53) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL15198842 | 0.75 | TUBB1 (0.53) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL28213558 | 0.75 | TUBB1 (0.53) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL21761474 | 0.75 | GAA (0.41) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL21761652 | 0.74 | TUBB1 (0.40) | NFE2L2MAPTLMNAKDM4ECYP1A1 | |
| SCHEMBL21750040 | 0.74 | TUBB1 (0.40) | NFE2L2MAPTLMNAKDM4ECYP1A1 | |
| SCHEMBL29860581 | 0.74 | TUBB1 (0.40) | NFE2L2MAPTLMNAKDM4ECYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628161-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-04-18 | — | — | US | disclosed |
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| EP-3590924-B1 | NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | PDE4A, PDE4B, PDE4C | NFE2L2 2439/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | NFE2L2 2849/4885PDE4A 1/4885PDE4B 2/4885 |
| US-11628161-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | PDE4A, PDE4B, PDE4C | NFE2L2 2439/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | NFE2L2 2428/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.